Comparison of parturient - controlled remifentanil with epidural bupivacain and sufentanil for labour analgesia: randomised controlled trial
Language English Country Czech Republic Media print-electronic
Document type Comparative Study, Journal Article, Randomized Controlled Trial
PubMed
23128818
DOI
10.5507/bp.2012.073
Knihovny.cz E-resources
- MeSH
- Anesthetics, Local administration & dosage MeSH
- Pain drug therapy MeSH
- Bupivacaine administration & dosage MeSH
- Adult MeSH
- Analgesia, Epidural * MeSH
- Obstetric Labor Complications drug therapy MeSH
- Humans MeSH
- Pain Measurement MeSH
- Young Adult MeSH
- Analgesics, Opioid administration & dosage MeSH
- Analgesia, Patient-Controlled * MeSH
- Piperidines administration & dosage MeSH
- Parturition MeSH
- Prospective Studies MeSH
- Remifentanil MeSH
- Sufentanil administration & dosage MeSH
- Pregnancy MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Young Adult MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
- Comparative Study MeSH
- Names of Substances
- Anesthetics, Local MeSH
- Bupivacaine MeSH
- Analgesics, Opioid MeSH
- Piperidines MeSH
- Remifentanil MeSH
- Sufentanil MeSH
INTRODUCTION: Epidural analgesia (EA) has significant contraindications including coagulation disorders and parturient refusal. One alternative is intravenous self-administered analgesia using the ultra short-acting opioid remifentanil (rPCA). We compared the efficiency and safety of standard epidural analgesia with parturient-controlled intravenous analgesia using remifentanil as well as personal satisfaction. MATERIALS AND METHODS: We enrolled twelve ASA I classified women with singleton pregnancy who delivered vaginally in the period 3/2010-5/2010 and who received rPCA (n=12) in standard analgesic protocol: 20 µg boluses using PCA pump with a lockout interval of 3 min. The control group consisted of 12 pregnant women who received EA (n=12): 0.125% bupivacaine with sufentanil 0.5 µg/mL in top-up boluses every hour until delivery. Data were acquired from standard Acute Pain Service (APS) form and patient medical records (demographic, labour course parameters), Visual Analogue Scale (VAS), Bromage Scale (BS) and adverse effects of analgesia. RESULTS: There were no demographic or labour course parameter differences between groups (P>0.05). The differences in VAS decrease (P=0.056) and parturient satisfaction (P=0.24) during the whole analgesia administration were statistically insignificant. The main limitation of the study was small sample and enrolment of healthy singleton pregnant women only. CONCLUSION: Remifentanil use in obstetric analgesia is a viable alternative to EA, especially in cases of EA contraindications and parturient disapproval.
References provided by Crossref.org